Vor Ort
Merkzettel Warenkorb
  • Produktbild: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
  • Produktbild: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Band 100

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988

Aus der Reihe Developments in Cardiovascular Medicine

198,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

10.10.2011

Herausgeber

J. Morganroth + weitere

Verlag

Springer Us

Seitenzahl

298

Maße (L/B/H)

23,5/15,5/1,8 cm

Gewicht

487 g

Auflage

Softcover reprint of the original 1st ed. 1989

Sprache

Englisch

ISBN

978-1-4612-8888-6

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

10.10.2011

Herausgeber

Verlag

Springer Us

Seitenzahl

298

Maße (L/B/H)

23,5/15,5/1,8 cm

Gewicht

487 g

Auflage

Softcover reprint of the original 1st ed. 1989

Sprache

Englisch

ISBN

978-1-4612-8888-6

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
  • Produktbild: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
  • I. Thrombolytic Agents: Clinical Trials ISSUES.- 1. Measurement of infarct size: effect of reperfusion with arterial blood.- 2. Pitfalls in the design and evaluation of clinical trials of intravenously administered cardiovascular drugs.- 3. The relative benefit and risks of intravenous streptokinase and tissue plasminogen activator in acute myocardial infarction.- 4. New agents and new insights for thrombolytic therapy in acute myocardial infarction: focus on anistreplase, urokinase, and prourokinase.- 5. Myocardial reperfusion: Role of adjunctive agents to improve reperfusion and prevent reperfusion injury.- Panel Discussion.- II. Thrombolytic Agents: Adjunctive Issues.- 6. Interactions between thrombolysis and sudden cardiac death.- 7. What are the overall strategies for post-thrombolytic care that include use of angioplasty?.- 8. Thrombolytic agents: biologic properties and issues regarding products derived by recombinant DNA technology.- Panel Discussion.- III. Risk vs. Benefit for Antiarrhythmic Drugs.- 9. What do new anti-arrhythmic agents have to show to establish a favorable risk versus benefit ratio?.- 10. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? — clinical viewpoint.- 11. Is it practical to develop a class III antiarrhythmic agent?.- Panel Discussion.- IV. Hypolipidemic Agents: Clinical & Regulatory Issues.- 12. What are the recommendations to the medical community to institute hypolipidemic therapy?.- 13. What are the comparative risks versus benefits for bile acid sequestrants, HMG CO-A reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives?.- 14. What levels of cholesterol should be studied and what should be the study designs?.- 15. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents?.- 16. How and when should long-term safety data be obtained for hypolipidemic agents?.- 17. What is required to gain approval of lipid altering drugs?.- Panel Discussion.- Participant List.